MDCO On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
text size: T | T
Back to Snapshot
Company Description

Contact Info

8 Sylvan Way

Parsippany, NJ 07054

United States

Phone: 973-290-6000

Fax: 973-656-9898

The Medicines Company, a global biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). It also has a pipeline of acute and intensive care hospital products in development, including ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The company has the right to develop, manufacture and commercialize ALN-PCSsc under its collaboration agreement with Alnylam Pharmaceuticals, Inc. In addition to these products and products in development, the company sells a ready-to-use formulation of Argatroban and have a portfolio of 10 generic drugs, which it refers to as its acute care generic products, that it has the non-exclusive right to market in the United States. The company sells three of its acute care generic products, midazolam, ondansetron and rocuronium. In 2015, the company entered into a supply and distribution agreement with Sandoz Inc., or Sandoz, under which it granted Sandoz the exclusive right to sell in the United States an authorized generic of Angiomax (bivalirudin). All of the company’s products and products in development, except for ALN-PCSsc and Ionsys, are administered intravenously. All of its acute care generic products are injectable products. Marketed Products Angiomax Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. The company licensed Angiomax from Biogen Idec, Inc. (Biogen Idec), and has exclusive license rights to develop, market and sell Angiomax worldwide. Angiomax is approved in the United States for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty and for patients undergoing percutaneous coronary intervention (PCI), with provisional use of glycoprotein IIb/IIIa receptor inhibitors, or GP IIb/IIIa inhibitors, including patients with or at risk of HIT/HITTS. The company sells Angiomax in the United States under its name as a branded Angiomax product, and also has a supply and distribution agreement with Sandoz under which it granted Sandoz the exclusive right to sell in the United States an authorized generic of Angiomax (bivalirudin). Angiomax is approved in the European Union for use as an anticoagulant in adult patients undergoing PCI, including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. The approval for acute coronary syndrome (ACS) in Europe also includes treatment of adult patients with unstable angina or non-STEMI planned for urgent or early intervention, when used with aspirin and clopidogrel. In Europe, the company markets Angiomax under the tradename Angiox. Angiomax is also approved for use in Australia, Canada, New Zealand, Russia, India and various countries in Central America, South America and the Middle East for PCI indications similar to those approved by the FDA or European Medicines Agency (EMA). In addition, Angiomax is approved in Canada for the treatment of patients with heparin induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing cardiac surgery. Cleviprex Cleviprex is an intravenous small molecule calcium channel blocker. The company licensed Cleviprex from AstraZeneca LP (AstraZeneca) in 2003 and has exclusive license rights to develop, market, and sell Cleviprex worldwide. In addition to the United States, the new formulation of Cleviprex is approved for sale in Australia, Austria, Belgium, Canada, France, Germany, Kazakhstan, Luxembourg, the Netherlands, Spain, Sweden, Switzerland and the United Kingdom with various indications, including for short term treatment of hypertension when oral therapy is not feasible or desirable in Australia, for management of acute elevation of blood pressure in perioperative settings in Canada, and for the reduction of blood pressure in perioperative settings in the European Union and Switzerland. The company has submitted marketing authorization ap

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

MDCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MDCO.
View Industry Companies
 

Industry Analysis

MDCO

Industry Average

Valuation MDCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.3x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MEDICINES COMPANY, please visit www.themedicinescompany.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.